Results 131 to 140 of about 4,843 (156)

PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies. [PDF]

Sci Rep
Singier A, Bénard-Laribière A, Jarne-Munoz A, Pariente A, Veyrac G, Bezin J.   +5 more
europepmc   +1 more source

When the Target Is Not the Driver: Rethinking LDL in Cardiac Allograft Vasculopathy. [PDF]

Circulation
Truby LK, Shapiro MD.
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerotic Plaque Progression: A Systematic Review and Meta-Analysis of Intravascular Imaging Studies. [PDF]

Rev Cardiovasc Med
Theofilis P, Vlachakis PK, Karakasis P, Iliakis P, Pamporis K, Oikonomou E, Dimitriadis K, Tsioufis K, Tousoulis D.   +8 more
europepmc   +1 more source

A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]

Front Pharmacol
Liu HH, Li S, Li JJ.
europepmc   +1 more source

Use of Negative Control Outcomes to Assess Cohort Comparability Among Evolocumab Initiators: A Real-World Database Study. [PDF]

Clin Epidemiol
Zou Y, Qian C, Liu J, Liu Y, Zhao L, Ye X, Huang Z, Lange JL, Dhalwani N, Yang F, Zhang Z, Chen K, Zhang H, Zhou J.   +13 more
europepmc   +1 more source

Is FH a curable disease? [PDF]

Glob Cardiol Sci Pract
Seidah NG.
europepmc   +1 more source

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. [PDF]

Journal of the American College of Cardiology, 2020
BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C).
Nandhini Sehar, Philippe Gabriel Steg, Sigrun Halvorsen   +2 more
exaly   +12 more sources

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher

Cardiovascular Drugs and Therapy, 2016
Even with statins and other lipid-lowering therapy (LLT), many patients with heterozygous familial hypercholesterolemia (heFH) continue to have elevated low-density lipoprotein cholesterol (LDL-C) levels.
Erik Stroes, Henry N Ginsberg, Robert Pordy   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

European Heart Journal, 2022
Anton Camaj
exaly